Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Short Interest Update

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) was the recipient of a significant increase in short interest during the month of July. As of July 31st, there was short interest totalling 10,020,000 shares, an increase of 10.8% from the July 15th total of 9,040,000 shares. Based on an average daily trading volume, of 1,100,000 shares, the days-to-cover ratio is presently 9.1 days.

Insiders Place Their Bets

In other Arrowhead Pharmaceuticals news, insider Tracie Oliver sold 9,394 shares of the business’s stock in a transaction that occurred on Tuesday, July 2nd. The stock was sold at an average price of $25.28, for a total transaction of $237,480.32. Following the transaction, the insider now owns 127,107 shares of the company’s stock, valued at $3,213,264.96. The sale was disclosed in a document filed with the SEC, which is available through this link. Company insiders own 4.50% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of ARWR. International Assets Investment Management LLC bought a new position in Arrowhead Pharmaceuticals during the 4th quarter worth $443,000. Louisiana State Employees Retirement System bought a new position in Arrowhead Pharmaceuticals during the 4th quarter worth $921,000. Strs Ohio raised its position in Arrowhead Pharmaceuticals by 7.1% during the 4th quarter. Strs Ohio now owns 28,500 shares of the biotechnology company’s stock worth $872,000 after purchasing an additional 1,900 shares during the last quarter. Handelsbanken Fonder AB raised its position in Arrowhead Pharmaceuticals by 7.5% during the 4th quarter. Handelsbanken Fonder AB now owns 21,600 shares of the biotechnology company’s stock worth $661,000 after purchasing an additional 1,500 shares during the last quarter. Finally, Yousif Capital Management LLC raised its position in Arrowhead Pharmaceuticals by 3.3% during the 4th quarter. Yousif Capital Management LLC now owns 52,224 shares of the biotechnology company’s stock worth $1,598,000 after purchasing an additional 1,659 shares during the last quarter. 62.61% of the stock is currently owned by institutional investors.

Arrowhead Pharmaceuticals Price Performance

NASDAQ ARWR opened at $22.70 on Monday. The business has a fifty day moving average price of $26.13 and a two-hundred day moving average price of $26.80. Arrowhead Pharmaceuticals has a fifty-two week low of $20.67 and a fifty-two week high of $39.83. The stock has a market capitalization of $2.82 billion, a PE ratio of -5.34 and a beta of 0.94.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its earnings results on Thursday, August 8th. The biotechnology company reported ($1.38) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.80). Arrowhead Pharmaceuticals had a negative return on equity of 140.72% and a negative net margin of 163.32%. During the same period in the prior year, the firm earned ($0.96) EPS. The firm’s quarterly revenue was down 100.0% compared to the same quarter last year. As a group, sell-side analysts expect that Arrowhead Pharmaceuticals will post -3.04 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms have recently commented on ARWR. B. Riley reaffirmed a “buy” rating and issued a $55.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Monday, August 12th. Cantor Fitzgerald reissued an “overweight” rating on shares of Arrowhead Pharmaceuticals in a research report on Thursday, June 20th. Morgan Stanley reduced their price target on Arrowhead Pharmaceuticals from $36.00 to $27.00 and set an “equal weight” rating on the stock in a research report on Monday, May 13th. StockNews.com raised Arrowhead Pharmaceuticals to a “sell” rating in a research report on Thursday, August 1st. Finally, Chardan Capital reissued a “buy” rating and set a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, July 17th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $44.25.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.